scholarly journals Mycobacterium Avium Complex Genitourinary Infections: Case Report and Literature Review

2021 ◽  
Vol 13 (2) ◽  
pp. 454-464
Author(s):  
Sanu Rajendraprasad ◽  
Christopher Destache ◽  
David Quimby
Keyword(s):  
Case Report ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Treatment Guidelines ◽  
Controlled Trials ◽  
Case Presentation ◽  
Delay In Diagnosis ◽  
Randomized Controlled ◽  
Mycobacterium Avium Intracellulare ◽  
Genitourinary Infections

Nontuberculous mycobacterial (NTM) genitourinary (GU) infections are relatively rare, and there is frequently a delay in diagnosis. Mycobacterium avium-intracellulare complex (MAC) cases seem to be less frequent than other NTM as a cause of these infections. In addition, there are no set treatment guidelines for these organisms in the GU tract. Given the limitations of data this review summarizes a case presentation of this infection and the literature available on the topic. Many different antimicrobial regimens and durations have been used in the published literature. While the infrequency of these infections suggests that there will not be randomized controlled trials to determine optimal therapy, our case suggests that a brief course of amikacin may play a useful role in those who cannot tolerate other antibiotics.

scholarly journals Tocilizumab in hospitalized patients with COVID-19: A meta analysis of randomized controlled trials

2021 ◽  
Author(s):  
Vijairam Selvaraj ◽  
Mohammad Saud Khan ◽  
Kwame Dapaah-Afriyie ◽  
Arkadiy Finn ◽  
Chirag Bavishi ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Randomized Controlled Trials ◽  
Standard Therapy ◽  
Treatment Guidelines ◽  
Meta Analysis ◽  
Hospitalized Patients ◽  
Controlled Trials ◽  
Mortality And Morbidity ◽  
Randomized Controlled ◽  
All Cause Mortality

ABSTRACTBackgroundTo date, only dexamethasone has been shown to reduce mortality in COVID-19 patients. Tocilizumab has been recently added to the treatment guidelines for hospitalized COVID-19 patients, but data remains conflicting.MethodsElectronic databases such as MEDLINE, EMBASE and Cochrane central were searched from March 1, 2020, until February 28th, 2021, for randomized controlled trials evaluating the efficacy of tocilizumab in hospitalized COVID-19 patients. The outcomes assessed were all-cause mortality at 28 days, mechanical ventilation, and time to discharge.ResultsEight studies (with 6,311 patients) were included in the analysis. In total, 3,267 patients received tocilizumab, and 3,044 received standard care/placebo. Pooled analysis showed a significantly decreased risk of all-cause mortality at 28 days (RR 0.90, 95% CI 0.83-0.97, p=0.009) and progression to mechanical ventilation (RR 0.79, 95% CI 0.70-0.90, p=0.0002) in the tocilizumab arm compared to standard therapy or placebo. In addition, there was a trend towards improved median time to hospital discharge (RR 1.18, 95% CI 1.05-1.34, p=0.007).ConclusionsTocilizumab therapy improves outcomes of mortality and need for mechanical ventilation, in hospitalized patients with COVID-19 infection compared with standard therapy or placebo. Our findings suggest the efficacy of tocilizumab therapy in hospitalized COVID-19 patients and strengthen the concept that tocilizumab is a promising therapeutic intervention to improve mortality and morbidity in COVID-19 patients.

scholarly journals Breast Cancer Research to Support Evidence-Based Medicine in Nigeria: A Review of the Literature

2021 ◽  
pp. 384-390
Author(s):  
Omolara A. Fatiregun ◽  
Temiloluwa Oluokun ◽  
Nwamaka N. Lasebikan ◽  
Emmanuella Nwachukwu ◽  
Abiola A. Ibraheem ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Randomized Controlled Trials ◽  
Evidence Based Medicine ◽  
Treatment Guidelines ◽  
Breast Cancer Research ◽  
Controlled Trials ◽  
Evidence Based ◽  
Randomized Controlled ◽  
Based Medicine

PURPOSE Breast cancer is the most common malignancy in women worldwide. In Nigeria, it accounts for 22.7% of all new cancer cases among women. Evidence-based medicine (EBM) entails using the results from healthcare research to enhance the clinical decision-making process and develop evidence-based treatment guidelines. Level 1 and 2 studies, such as randomized controlled trials, meta-analyses, and systematic reviews of randomized controlled trials, yield more robust types of evidence. This study reviewed the levels of evidence of breast cancer publications in Nigeria. METHODS We conducted an electronic literature search of all studies published on breast cancer in Nigeria from January 1961 to August 2019. We reviewed all the articles found under the search term “Breast Cancer in Nigeria” on medical databases. RESULTS Our search identified 2,242 publications. One thousand two hundred fifty duplicates were removed, and 520 were excluded. A total of 472 articles were considered eligible for this review. Most of these articles were case series or reports (30.7%), qualitative studies (15.7%), followed by cross-sectional studies (13.3%), laboratory studies (12.9%), case-control studies (6.1%), case reports (7%), and cohort (5.7%). CONCLUSION Breast cancer research in Nigeria is yet to produce much evidence of the types considered to best support EBM. The scarcity of data hampers the implementation of EBM in Nigeria. Currently, most treatment guidelines are adapted from those developed in other countries, despite genetic differences among populations and different environmental influencing factors.

Unusual Presentation for Unusual Infection: Disseminated Mycobacterium Avium-Intracellulare complex (MAC) in Patient with Sickle Cell Anemia Mimicking Blood Transfusion Reaction

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4980-4980
Author(s):  
Nayf Edrees ◽  
Thomas H. Howard
Keyword(s):  
Blood Culture ◽  
Sickle Cell ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Conflicts Of Interest ◽  
Venous Catheter ◽  
Whole Body ◽  
Transfusion Reaction ◽  
Mycobacterium Avium Intracellulare ◽  
Slow Grower

Abstract Nontuberculous mycobacteria (NTM) are ubiquitous free living soil and water– borne organisms that cause numerous clinical syndromes including lymphadenitis, skin, soft tissue and pulmonary infections, however disseminated infection is almost exclusively in patient with severe immunocompromise (i.e:HIV, Hematological malignancy, and bone marrow transplant). Mycobacterium avium complex (MAC) is hard to diagnose as it is considered slow grower NTM. We describe a case of disseminated Mycobacterium avium-intracellulare complex infection in teenager with sickle hemoglobinopathy with unique presentation mimicking pRBCs transfusion reaction. Patient presented on three different occasions with tachycardia, hypotension and fever within 2-24 hours following pRBCs pheresis, all three episodes were investigated and were negative for transfusion reactions. Patient had central venous catheter (CVC), frequent admissions for vaso-occlusive painful episode, on hydrocortisone for adrenal insufficiency and off Hydroxyurea for two months. Diagnosis of mycobacterium avium complex bacteremia was confirmed by two positive blood cultures, whole body CT scan showed liver nodules, spleen nodules and lung nodules. Pulmonary dissemination was confirmed by Biopsy and culture, Lymphocyte markers showed severe lymphopenia with absolute CD4 count of 64. Patient underwent treatment with three month of four antibiotics followed by 9 months of three antibiotics with removal of the central line, follow up scan showed decrease size and numbers of nodules, patient started tolerating pheresis within one month of the antibiotics initiation. NTM infection should be added to the list of pathogens in sickle cell patients with CVCs and fever and should be considered in frequent pRBC transfusion like reaction with negative workup. Routine blood culture can identify rapid growing NTM but specific mycobacterial blood culture is required in case of other NTM species (slow grower). As dissemination almost always occurs in those with impaired cellular immunity, HIV testing and lymphocyte markers should be performed Removal of involved CVCs is essential for the treatment as well as appropriate antimicrobial medications. Disclosures No relevant conflicts of interest to declare.

Treatment and prophylaxis of Mycobacterium avium complex

1996 ◽  
Vol 7 (1_suppl) ◽  
pp. 23-27 ◽  
Author(s):  
L S Young
Keyword(s):  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Antimicrobial Agents ◽  
Careful Study ◽  
Double Blind ◽  
Acquired Immunodeficiency ◽  
Mycobacterium Avium Intracellulare ◽  
Immunodeficiency Syndrome ◽  
Emergence Of Resistance ◽  
Cytochrome P 450

The most common pathogens involved in disseminated bacterial infection in people with acquired immunodeficiency syndrome (AIDS) are organisms of the Mycobacterium avium-intracellulare complex (MAC). Azithromycin and clarithromycin, a new azalide and macrolide, respectively, are among the most potent monotherapies for MAC bacteraemia, although many bloodstream isolates demonstrate increased minimum inhibitory concentrations after 4 months of treatment. Current recommended prophylaxis, based on the results of two randomized, double-blind, prospective studies, is rifabutin 300 mg daily for people with AIDS with <100 CD4 lymphocytes/mm3. In the beige mouse model, we have shown that both azithromycin and clarithromycin prevent MAC bacteraemia following repetitive oral challenge. Clinical trials are now underway to confirm these effects in man; comparative treatments include placebo, rifabutin and an azalide/macrolide plus rifabutin. While combinations might be more effective and reduce the emergence of resistance, the spectre of cytochrome P-450 drug interactions necessitates careful study before combination prophylactic approaches are accepted. Such interactions are associated with rifabutin and some macrolides, although azithromycin may be less problematic in this respect as it appears to have little potential to interact with other antimicrobial agents.

scholarly journals Chylous ascites secondary to Hodgkin’s lymphoma in a HIV/aids patient: case report and literature review

2017 ◽  
Vol 50 (5) ◽  
pp. 317
Author(s):  
Mário Luciano de Mélo Silva Júnior ◽  
Hildenice Ferreira Bernardes Leonídio ◽  
Mariana Montenegro de Melo Lira ◽  
Luciana Cardoso Martins Arraes ◽  
Carlos Eduardo Guimarães Padilha ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Mycobacterium Avium ◽  
Mycobacterium Avium Complex ◽  
Chylous Ascites ◽  
Hodgkin's Lymphoma ◽  
Patient Case ◽  
Ann Arbor ◽  
Terapia Antirretroviral ◽  
Hiv Aids

Tipo de estudo: relato de caso. Relato de caso: Homem, 42 anos, diagnosticado com aids há dois anos, desenvolveu aumento de volume abdominal há seis meses da admissão. Tomografia computadorizada mostrou líquido livre na cavidade peritoneal, além de linfonodos mesentéricos e esplenomegalia. O líquido ascítico tinha aspecto leitoso e alto nível de triglicerídeos. Após amplo diagnóstico diferencial, diagnosticamos linfoma de Hodgkin tipo celularidade mista por biópsia linfonodal via videolaparoscópica, Ann Arbor IIIS. Quimioterapia e continuação da terapia antirretroviral de alta potência resultaram em ganho de peso e redução do volume abdominal. Ascite quilosa é uma entidade rara, que possui vários diagnósticos diferenciais. Discussão: Em nossa revisão, a maioria (15/18, 83%) dos casos de ascite quilosa em paciente com HIV/aids deveu-se a causa infecciosa (especialmente pelo Mycobacterium avium complex e tuberculose), em pacientes gravemente imunocomprometidos (linfócitos T-CD4 médio=84células/mm3). Até onde sabemos, este é o primeiro caso de ascite quilosa secundária a linfoma de Hodgkin em paciente com aids.

Sign in / Sign up

Export Citation Format

Share Document